CART 30 - Cellular Biomedicine Group

Drug Profile

CART 30 - Cellular Biomedicine Group

Alternative Names: Anti-CD30 CART cells; Anti-CD30 chimeric antigen receptor T cell therapy - Cellular Biomedicine Group; CD30 specific CART cells

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chinese PLA General Hospital
  • Class Cancer vaccines; CAR-T cell therapies; Gene therapies; T lymphocyte cell therapies; Vaccines
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hodgkin's disease; Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Sep 2017 Phase-I/II development is ongoing in China (NCT02259556)
  • 22 May 2015 Efficacy and adverse events data from a phase I/II trial in Non-Hodgkin's lymphoma released by Cellular Biomedicine Group
  • 01 Oct 2014 Phase-I/II clinical trials in Hodgkin's disease (In adults, In the elderly, Recurrent, Treatment-resistant) in China (IV) (NCT02259556)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top